Spin-out founded based on research about innate defence regulator (IDR) peptides

A spin-out from the labs of Drs. Brett Finlay and Robert Hancock, called Inimex Pharmaceuticals, focused on fighting superbugs with Innate Defense Regulators (IDRs). IDRs are drugs that selectively modulate the body’s innate defenses without causing inflammation. Inimex Pharmaceuticals raised more than $28 million. 

 

 

Protein research leaps forward with the opening of the Proteomics Core Facility

The Proteomics Core Facility was established by Dr. Stephen Withers in 2002. In 2008, Dr. Leonard Foster became the Director of the Proteomics Core Facility which has a strong track record of service provision and technology development. The well-equipped facility houses a number of mass spectrometers and experienced staff with strong knowledge in relative quantitative proteomics, functional proteomics, and bioinformatics. 

A photo of the mass spectrometers at UBC’s Proteomics Core Facility. This photo was taken in 2018.